DoseMe Expands Global Footprint as Premier Hospitals and Cancer Centers across Australia Continue to Adopt Bayesian Dosing
DoseMe , a leading provider of model-informed precision dosing (MIPD) software, is pleased to announce the continued growth in Australia.
- DoseMe , a leading provider of model-informed precision dosing (MIPD) software, is pleased to announce the continued growth in Australia.
- The precision dosing software has informed over 400,000 dosing decisions, benefiting more than 10,000 patients and gaining the trust of over 1,000 clinicians nationwide.
- “It is exciting to see the global demand around precision dosing, with Australia continuing to be a trailblazer,” said Paul Edwards, CEO of DoseMe.
- This surge in clientele was boosted by strategic partnerships worldwide, underscoring DoseMe's commitment to global expansion and continuous innovation to deliver advanced precision dosing.